SynthesisWorld journal of surgical oncology2025
Optimal neoadjuvant regimens for locally advanced gastric and gastroesophageal junction cancer: a systematic review and bayesian network meta-analysis.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neoadjuvant Treatment Versus Upfront Surgery in Gastric Cancer Patients: Early Postoperative and Pathological Results: A Retrospective Study in a Tertiary Center.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLarge randomized controlled trials (RCTs) have reported data on neoadjuvant therapies for locally advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, no clear recommendation is provided regarding the optimal choice of neoadjuvant regimen. This network meta-analysis (NMA) endeavors to identify the best neoadjuvant therapy for the locally advanced GC and GEJC.
methodsPubMed, Embase, Cochrane Library, and Web of Science databases were searched systematically until September 6, 2024 and update until November 14, 2025. This study encompassed RCTs investigating neoadjuvant treatment for locally advanced GC or GEJC that reported outcomes on overall survival (OS), pathological complete response (pCR), as well as R0 resection rates. Study quality was rated utilizing the Cochrane Risk of Bias Tool 2.0. Bayesian network meta-analysis (BNMA) was conducted through Stata and RStudio for efficacy comparison and ranking of all regimens.
results26 RCTs comprising 7,324 patients with GC or GEJC were encompassed. Through the surface under the cumulative ranking curve (SUCRA), DOX ranked highest for OS. FLOT combined with Durvalumab (FLOT_Durvalumab) demonstrated a superior pCR rate, while DOS combined with apatinib (DOS_Apatinib) ranked highest for R0 resection rate. DOX significantly prolonged OS compared with CS (HR = 0.54, 95% CrI: 0.29–0.99), surgery (HR = 0.49, 95% CrI: 0.29–0.84), and XELOX (HR = 0.59, 95% CrI: 0.35–0.99).
conclusionsDOX appears to be the most effective neoadjuvant treatment for ameliorating OS in patients with GC or GEJC. FLOT_Durvalumab was associated with the highest pCR rate, while DOS_Apatinib appears most effective in achieving R0 resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.